Allergists’ attitudes toward environmental control: Insights into its current application in clinical practice - 15/08/11
Doi : 10.1016/j.jaci.2007.11.025
Dominique M. Brandt, MA a, Linda Levin, PhD e, Elizabeth Matsui, MD, MHS b, Wanda Phipatanakul, MD, MS c, Alisa M. Smith, PhD d, Jonathan A. Bernstein, MD a 
American Academy of Allergy, Asthma & Immunology Indoor Allergen Committee
a Department of Internal Medicine, Division of Immunology/Allergy Section, University of Cincinnati College of Medicine, Cincinnati, Ohio
e Department of Environmental Biostatistics, University of Cincinnati College of Medicine, Cincinnati, Ohio
b Division of Pediatric Allergy and Immunology, Johns Hopkins University, Baltimore, Md
c Division of Pediatric Allergy and Immunology, Children’s Hospital, Harvard Medical School, Boston, Mass
d Indoor Environments Division, US Environmental Protection Agency, Washington, DC
Le texte complet de cet article est disponible en PDF.
| Supported by the American Academy of Allergy, Asthma & Immunology. |
|
| Disclosure of potential conflict of interest: W. Phipatanakul has received research support from the National Institutes of Health, Woodstock Company, and Novartis. J. A. Bernstein has received research support from Merck, GlaxoSmithKline, and MedPointe; has served as an expert witness in environmental cases; has served as a member of AFI; and has consulting arrangements with GlaxoSmithKline, MedPointe, AstraZeneca, Teva, and UCB. The rest of the authors have declared that they have no conflict of interest. |
© 2008
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 121 - N° 4
P. 1053-1054 - avril 2008 Retour au numéro
Article précédent
- Cat ownership is a risk factor for the development of anti-cat IgE but not current wheeze at age 5 years in an inner-city cohort
- Matthew S. Perzanowski, Ginger L. Chew, Adnan Divjan, Alina Johnson, Inge F. Goldstein, Robin S. Garfinkel, Lori A. Hoepner, Thomas A.E. Platts-Mills, Frederica P. Perera, Rachel L. Miller
- Primary resistance to imatinib in Fip1-like 1–platelet-derived growth factor receptor ⍺—positive eosinophilic leukemia
- Dagmar Simon, Souzan Salemi, Shida Yousefi, Hans-Uwe Simon
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?